Naproxcinod for the treatment of primary osteoarthritis
Status Suspended
Decision Selected
Process STA pre-2018
Referral date 01 November 2010
Topic area
  • Musculoskeletal

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager: TBC
Technical Lead: TBC


Key events during the development of the guidance:

Date Update
27 May 2011 The Institute has been informed by the manufacturer that it has withdrawn its application for a centralised marketing authorisation for naproxcinod.

Further information

NICE has therefore decided to suspend this appraisal on its current work programme for the time being.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

For further information on our processes and methods, please see our CHTE processes and methods manual